Recombinant human thyroid-stimulating hormone: Use in papillary and follicular thyroid cancer

Hormone Research

Volumn 67, Issue SUPPL. 1, 2007, Pages 132-142

  Schlumberger, Martin ^a   Borget, Isabelle ^a   De Pouvourville, Gérard ^a   Pacini, Furio ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Recombinant human thyroid stimulating hormone; Thyroid cancer

Indexed keywords

FLUORODEOXYGLUCOSE; IODINE 131; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROID HORMONE; THYROTROPIN; THYROTROPIN ALPHA; THYROXINE; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DRUG DOSE COMPARISON; ECHOGRAPHY; FATIGUE; FOLLICULAR THYROID CANCER; FOLLOW UP; HEADACHE; HUMAN; HYPOTHYROIDISM; LYMPH NODE METASTASIS; NAUSEA; NONHUMAN; PAPILLARY THYROID CANCER; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; SENSITIVITY ANALYSIS; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER;

EID: 33847032436     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097570     Document Type: Conference Paper

References (87)

1. Schlumberger M: Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306.
2. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM: The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:1-33.
3. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, European Thyroid Cancer Taskforce: European consensus for the management of patients with differentiated thyroid cancer of the follicular epithelium. Eur J Endocrinol 2006;154:787-803.
4. Dow KH, Ferrell BR, Anello C: Quality of life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997;7:613-619.
5. Luster M, Felbinger R, Dietlein M, Reiners C: Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 2005;15:1147-1155.
6. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC, Ladenson PW: A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with rhTSH compared to thyroid hormone withdrawal. J Clin Endocrinol Metab 2006;91:878-884.
7. 131I scintiscans and thyroglobulin testing. Thyroid 1996;6:69-73.
8. 131I scintigraphy or therapy by 1-3 weeks of thyroxine discontinuation. J Nucl Med 2004;45:567-570.
9. Busnardo B, Bui F, Girelli ME: Different rates of serum thyrotropin suppression after total body scan in patients with thyroid cancer: effect of regular doses of thyroxine and triiodothyronine. J Endocrinol Invest 1983;6:35-40.
10. Robbins J: Pharmacology of bovine and human thyrotropin: an historical perspective. Thyroid 1999;9:451-453.
11. Wondisford FE, Radovick S, Moates JM, Usala SJ, Weintraub BD: Isolation and characterization of the human thyrotropin betasubunit gene. Differences in gene structure and promoter function from murine species. J Biol Chem 1988;263:12538-12542.
12. Guidon PT Jr, Whitfield GK, Porti D, Kourides IA: The human thyrotropin beta-subunit gene differs in 5′ structure from murine TSH-beta genes. DNA 1988;7:691-699.
13. Wondisford FE, Usala SJ, DeCherney GS, Castren M, Radovick S, Gyves PW, Trempe JP, Kerfoot BP, Nikodem VM, Carter BJ: Cloning of the human thyrotropin beta-subunit gene and transient expression of biologically active human thyrotropin after gene transfection. Mol Endocrinol 1988;2:32-39.
14. Thotakura NR, Desai RK, Bates LG, Cole ES, Pratt BM, Weintraub BD: Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells. Endocrinology 1991;128:341-348.
15. Huber GK, Fong P, Concepcion ES, Davies TF: Recombinant human thyroid-stimulating hormone: initial bioactivity assessment using human fetal thyroid cells. J Clin Endocrinol Metab 1991;72:1328-1331.
16. Braverman LE, Pratt BM, Ebner S, Longcope C: Recombinant human thyrotropin stimulates thyroid function and radioactive iodine uptake in rhesus monkey. J Clin Endocrinol Metab 1991;74:1135-1139.
17. Ramirez L, Braverman LE, White B, Emerson CH: Recombinant human thyrotropin is a potent stimulator of thyroid function in normal subjects. J Clin Endocrinol Metab 1997;82:2836-2839.
18. Pena S, Arum S, Cross M, Magnani B, Pearce EN, Oates ME, Braverman LE: 123I thyroid uptake and thyroid size at 24, 48, and 72 h after the administration of recombinant human thyroid-stimulating hormone to normal volunteers. J Clin Endocrinol Metab 2006;91:506-510.
19. Torres MS, Ramirez L, Simkin PH, Braverman LE, Emerson CH: Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. J Clin Endocrinol Metab 2001;86:1660-1664.
20. Meier CA, Braverman LE, Ebner SA, Vero nikis I, Daniels GH, Ross DS, Deraska DJ, Davies TF, Valentine M, DeGroot LJ: Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 1994;78:188-196.
21. Castagna MG, Pinchera A, Marsili A, Giannetti M, Molinaro E, Fierabracci P, Grasso L, Pacini F, Santini F, Elisei R: Influence of human body composition on serum peak thyrotropin (TSH) after recombinant human TSH administration in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2005;90:4047-4050.
22. Iorcansky S, Herzovich V, Qualey RR, Tuttle RM: Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6553-6555.
23. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR , Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC: A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84:3877-3885.
24. Ladenson PW, Bravermann LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, Wondisford FE, Davies TF, DeGroot LJ, Daniels GH, Ross DS, Weintraub BD: Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997;337:888-895.
25. Paterakis T, Ebels H, Mallick UK, Proud G, Jones N, Lennard T, Lucraft H, Fenwick J, Weightman D, Kendall-Taylor P, Perros P: Lack of antigenicity of recombinant human thyrotropin after multiple injections in patients with differentiated thyroid cancer. Thyroid 2000;10:623.
26. Cohen O, Dabhi S, Karasik A, Zila Zwas S: Compliance with follow-up and the informative value of diagnostic whole-body scan in patients with differentiated thyroid carcinoma given recombinant human TSH. Eur J Endocrinol 2004;150:285-290.
27. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, Pasquini C, Piazza F, Caciagli M, Mariani G: Radioiodine treatment with 30 mCi after recombinant human TSH stimulation in thyroid cancer: effectiveness for post-surgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 2003;88:4110-4115.
28. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C: Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006;91:926-932.
29. Driedger AA, Kotowycz N: Two cases of thyroid carcinoma that were not stimulated by recombinant human thyrotropin. J Clin Endocrinol Metab 2004;89:585-590.
30. Taïeb D, Jacob T, Zotian E, Mundler O: Lack of efficacy of recombinant human thyrotropin versus thyroid hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid carcinoma lung metastases. Thyroid 2004;14:465-467.
31. Robbins RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, Smith A, Drucker WD: Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001;86:619-625.
32. Eustatia-Rutten CFA, Smit JW, Romijn JA, van der Kleij-Corssmit EP, Pereira AM, Stokkel MP, Kievit J: Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol 2004;61:61-74.
33. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M: Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid carcinoma? J Clin Endocrinol Metab 2000;85:175-178.
34. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A: Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002;87:1499-1501.
35. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C, Taddei D, Elisei R, Capezzone M, Pinchera A: Prediction of disease status by recombinant human TSHstimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001;86:5686-5690.
36. Mazzaferri EL, Kloos RT: Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002;87:1490-1498.
37. Haugen BR, Ridgway EC, McLaughlin B, McDermott MT: Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human TSH. Thyroid 2002;12:37-43.
38. Wartofsky L: Using baseline and recombinant human TSH-stimulated Tg measurements to manage thyroid cancer without diagnostic (131)I scanning. J Clin Endocrinol Metab 2002;87:1486-1489.
39. Giovanni V, Arianna LG, Antonio C, Francesco F, Michele K, Giovanni S, Marco S, Giovanni L: The use of recombinant human TSH in the follow up of differentiated thyroid cancer: experience from a large patient cohort in a single center. Clin Endocrinol 2002;56:247-252.
40. David A, Blotta A, Bondanelli M, Rossi R, Roti E, Braverman LE, Busutti L, degli Uberti EC: Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. J Nucl Med 2001;42:1470-1475.
41. Bachelot A, Cailleux AF, Klain M, Baudin E, Ricard M, Bellon N, Caillou B, Travagli JP, Schlumberger M: Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid 2002;12:707-711.
42. Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS: Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab 2005;90:5566-5575.
43. Frasoldati A, Pesenti M, Gallo M, Carrogio A, Salvo D, Valcavi R. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 2003;97:90-96.
44. Torlontano M, Attard M, Crocetti U, Tumino S, Bruno R, Costante G, D'Azzo G, Meringolo D, Ferretti E, Sacco R, Arturi F, Filetti S: Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 2004;89:3402-3407.
45. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A: Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003;88:3668-3673.
46. Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM: Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 2002;87:3242-3247.
47. Bachelot A, Leboulleux S, Baudin E, Hartl DM, Caillou B, Travagli JP, Schlumberger M: Neck recurrence from thyroid carcinoma: serum thyroglobulin and high dose total body scan are not reliable criteria for cure after radioiodine treatment. Clin Endocrinol 2005;62:376-379.
48. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M: Positive predictive value of serum thyroglobulin levels, measured during the first year of followup following thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 2003;88:1107-1111.
49. Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, Molinaro E, Pinchera A: Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab 2001;86:4092-4097.
50. Toubeau M, Touzery C, Arveux P, Chaplain G, Vaillant G, Berriolo A, Riedinger JM, Boichot C, Cochet A, Brunotte F: Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer. J Nucl Med 2004;45:988-994.
51. Kloos RT, Mazzaferri EL: A single recombinant human thyrotropin- stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 2005;90:5047-5057.
52. David A, Blotta A, Rossi R, Zatelli MC, Bondanelli M, Roti E, Braverman LE, Busutti L, degli Uberti EC: Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. Thyroid 2005;15:158-164.
53. 131I therapy for elevated thyroglobulin levels. Thyroid 1997;7:273-276.
54. Van Tol KM, Jager PL, Piers DA, Pruim J, de Vries EG, Dullaart RP, Links TP: Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 2002;12:381-387.
55. Moog F, Linke R, Manthey N, Tiling R, Knesewitsch P, Tatsch K, Hahn K: Influence of thyroid-stimulating hormone levels on up-take of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 2000;41:1989-1995.
56. Petrich T, Börner AR, Otto D, Hoffmann M, Knapp WH: Influence of rhTSH on [18F] fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med 2002;29:641-647.
57. Chin BB, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P: Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004;89:91-95.
58. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A: A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433-1441.
59. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Pacini F, Reiners C, Sanchez Franco F, Toft A, Wiersinga WM: Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004;50:105-112.
60. Biondi B, Filetti S, Schlumberger M: Thyroid-hormone therapy and thyroid cancer: a reassessment. Nature Clinical Practice Endocrinology & Metabolism 2005;1:32-40.
61. Schlumberger M: Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxin and negative neck ultrasound? (Commentary). Clin Endocrinol 2005;62:119-120.
62. 131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation. A consensus report. Eur J Endocrinol 2005;153:651-659.
63. Berg G, Lindstedt G, Suurküla M, Jansson S: Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone (rhTSH). J Endocrinol Invest 2002;25:44-52.
64. Robbins RJ, Larson SM, Sinha N, Shaha A, Divgi C, Pentlow KS, Ghossein R, Tuttle RM: A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med 2002;43:1482-1488.
65. Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L, Elisei R, Pinchera A: Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002;87:4063-4068.
66. Luster M, Sherman SI, Skarulis MC, Reynolds JR, Lassmann M, Hanscheid H, Reiners C: Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging 2003;30:1371-1377.
67. Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C: Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006;47:648-654.
68. Ringel MD, Ladenson PW: Diagnostic accuracy of 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism. J Clin Endocrinol Metab 1996;81:1724-1725.
69. Colleran KM, Burge MR: Isolated thyrotropin deficiency secondary to primary empty sella in a patient with differentiated thyroid carcinoma: an indication for recombinant thyrotropin. Thyroid 1999;9:1249-1252.
70. Risse JH, Grunwald F, Bender H, Schuller H, Van Roost D, Biersack HJ: Recombinant human thyrotropin in thyroid cancer and hypopituitarism due to sella metastasis. Thyroid 1999;9:1253-1256.
71. Lippi F, Capezzone M, Angelini F, Taddei D, Molinaro E, Pinchera A, Pacini F: Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. Eur J Endocrinol 2001;144:5-11.
72. Pellegritti G, Scollo C, Giuffrida D, Vigneri R, Squatrito S, Pezzino V: Usefulness of recombinant human thyrotropin in the radiometabolic treatment of selected patients with thyroid cancer. Thyroid 2001;11:1025-1030.
73. Jarzab B, Handkiewicz-Junak D, Roskosz J, Puch Z, Wygoda Z, Kukulska A, Jurecka-Lubieniecka B, Hasse-Lazar K, Turska M, Zajusz A: Recombinant human-TSH aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients. Eur J Nucl Med Mol Imaging 2003;30:1077-1086.
74. Luster M, Lassmann M, Haenscheid H, Michalowski U, Incerti C, Reiners C: Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab 2000;85:3640-3645.
75. Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, Pacini F: rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 2005;12:49-64.
76. Vargas GE, Uy H, Bazan C, Guise TA, Bru der JM: Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain. J Clin Endocrinol Metab 1999;84:3867-3871.
77. Braga M, Ringel MD, Cooper DS: Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. J Clin Endocrinol Metab 2001;86:5148-5151.
78. Goffman T, Ioffe V, Tuttle M, Bowers JT, Mason ME: Near-lethal respiratory failure after recombinant human thyroid-stimulating hormone use in a patient with metastatic thyroid carcinoma. Thyroid 2003;13:827-830.
79. Maxon HR, Smith HS: Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am 1990;19:685-718.
80. de Keizer B, Brans B, Hoekstra A, Zelissen PM, Koppeschaar HP, Lips CJ, van Rijk PP, Dierckx RA, de Klerk JM: Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. Eur J Nucl Med Mol Imaging 2003;30:367-373.
81. Menzel C, Kanert WT, Diehl M, Fietz T, Hamscho N, Berner U, Grunwald F: rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I. J Nucl Med 2003;44:1065-1068.
82. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M: Long term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91:2892-2899.
83. Billewicz WZ, Chapman RS, Crooks J, Day ME, Gossage J, Wayne E, Young JA: Statistical methods applied to the diagnosis of hypothyroidism. Q J Med 1969;38:2072-2073.
84. Ware JE, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. A conceptual framework and item selection. Med Care 1992;30:473-483.
85. Brazier J, Roberts J, Deverill M: The estimation of a preference-based measure of health from the SF36. J Health Econ 2002;21:271-292.
86. Medical Services Advisory Committee: Recombinant human thyroid-stimulating hormone (rhTSH). Diagnostic agent for use in well-differentiated thyroid cancer. MSAC application 1043, 2002, p 110.
87. Nijhuis TF, van Weperen W, de Klerk JMH: Costs associated with the withdrawal of thyroid hormone suppression therapy during the follow-up treatment of well-differentiated thyroid cancer. Tijdschr Nucl Geneeskd 1999;21:98-100.